106P - Sentinel lymph node after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Locally Advanced
Pathology/Molecular Biology
Surgical Oncology
Presenter Amer Chikh Youssef
Citation Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576
Authors A. Chikh Youssef
  • Gynecologic Oncology, obstetrics gynecology university hospital, 4092 - Damascus/SY



Sentinel lymph node provides reliable node staging information for clinically node negative and chemo naive breast cancer patients while its role after neoadjuvant chemotherapy remains unclear due to high false negative rate reported in previous studies.


From may 2015 to may 2016 33 patients were enrolled all of them received neoadjuvant chemotherapyfor locally advanced breast cancer patients underwent sentinel lymph node using blue dye and axillary lymph node dissection.


33 patients underwent sentinel lymph node and axillary lymph node dissection following neoadjuvant chemotherapy no cancer was found in the axillary lymph nodes of 8 patients PCR 24,3% in 5 patients cancer was not identified in the sentinel lymph node but was found in lymph nodes obtained from axillary lymph node dissection (false negative rate 15,2%).


Among women receiving neoadjuvant chemotherapy the false negative rate was not 10% or less so we can't support the sentinel lymph node as alternative to axillary lymph node dissection another change in approach and patients selection may improve sentinel lymph node sensitivity .

Clinical trial indentification

Identifying the falsenegative rate for sentinel lymph node following neoadjuvant chemotherapy in locally advanced breast cancer.

Legal entity responsible for the study

Obstetrics Gynecology University Hospital


Obstetrics Gynecology University Hospital


All authors have declared no conflicts of interest.